Anne-Marie Duliege
Board Director - CIRM
Board/Governance, Executive Coaching/Organizational Development, Fundraising/Philanthropy, Human Resources/Recruiting/Retaining Top Talent, Management of Staff/Teams and/or Projects, Public Speaker/Leadership Presence, Strategic Partnerships/Networks, Technology/Biotech

About
Me.
Visionary CMO with 20+ years of board experience and executive leadership (VP,then Chief Medical Officer) in biopharmaceutical companies and foundations.
• My strengths include leading global drug and vaccine development to
approval and commercialization; aligning board members, executive teams
and operational teams around a shared vision; excelling at communicating
with investors and building solid partnerships with stakeholders; having
large domestic and international networks; proven problem-solving abilities
(pipeline analysis, business development deals, partnership agreements).
• My expertise is creating value through cross-sector collaborations
(biopharma, non-profit, and patient advocacy organizations).
• My track record includes driving the FDA approval and supporting the
market launch of two novel drugs, generating revenue growth; leading the
anti-malarial interventions’ portfolio transformation at the Bill and Melinda
Gates Foundation; and spearheading a complex adaptive Phase 2/3 trial in
pancreatic cancer at PanCAN.
I am seeking board positions with organizations that drive transformative healthcare innovations, require strategic guidance for complex drug development efforts/market expansion, and preferably demonstrate a commitment to expanding medical access in low and middle-income countries.
As a Board Member:
• Board of Fe Pharmaceuticals (2020-present): Chair as of 2023; member,
Compensation Committee; and Co-chair, Scientific Advisory Board; leading
advisor for the clinical and regulatory strategies (serious infections/sepsis);
play a key role in networking for seed and Series A fundraising with
institutional investors, high net-worth individuals, and foundations.
• Board of the California Institute of Regenerative Medicine (2012-present):
help guide the spending of $8.5 billion to accelerate stem cell research;
member, Application Review, Finance, Governance, and IP/Industry
committees.
• Board of the AIDS Vaccine Advocacy Coalition (2005-2023); reviewed the
organizational mission and the strategic planning; guided the organizational
evaluation; member, DEI committee.
As a Member of Executive Teams
• Extensive product development experience (30+ years): adept at
navigating complex regulatory environments; depth and breadth across
hematology, immunology, nephrology, infectious diseases (including HIV
and malaria) & rare/orphan diseases.
• BMGF Deputy Director: led the antimalaria interventions and diagnostics
efforts toward eradicating malaria worldwide.
• PanCAN CMO: provided the strategic direction and operational oversight
for the clinical sciences and medical affairs departments.
• Rigel Pharmaceuticals CMO: brought the company’s flagship product to
market; contributed to doubling the company’s valuation in 18 months;
supported the CEO in raising $165 million in 3 rounds.
• Affymax CMO: brought the company’s flagship product to market;
successful IPO in 2006; $500+ million partnership with Takeda.